Alcibiades Ojeda Rodríguez

1 week ago | neurologyadvisor.com | Jayne Feld |Alcibiades Ojeda Rodríguez

In recent years, glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and tirzepatide have made headlines for their impressive ability to promote weight loss and improve glycemic control among people with type 2 diabetes. But with the recent FDA of Zepbound® (tirzepatide) to treat obstructive sleep apnea (OSA), these medications are stepping into a new spotlight — one that highlights their emerging role in ways that go beyond shedding pounds.

3 weeks ago | rheumatologyadvisor.com | Jayne Feld |Alcibiades Ojeda Rodríguez

In recent years, glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and tirzepatide have made headlines for their impressive ability to promote weight loss and improve glycemic control among people with type 2 diabetes. But with the recent FDA of Zepbound® (tirzepatide) to treat obstructive sleep apnea (OSA), these medications are stepping into a new spotlight — one that highlights their emerging role in ways that go beyond shedding pounds.

1 month ago | gastroenterologyadvisor.com | Jayne Feld |Alcibiades Ojeda Rodríguez

In recent years, glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and tirzepatide have made headlines for their impressive ability to promote weight loss and improve glycemic control among people with type 2 diabetes. But with the recent FDA of Zepbound® (tirzepatide) to treat obstructive sleep apnea (OSA), these medications are stepping into a new spotlight — one that highlights their emerging role in ways that go beyond shedding pounds.